Umoja Biopharma is at the forefront of developing innovative immunotherapy solutions aimed at treating solid tumors and hematological cancers that have shown limited responsiveness to existing therapies. Their integrated platform utilizes in vivo CAR T-cell therapeutics, which allows for the reprogramming of the immune system directly within the patient's body. This approach is designed to overcome the challenges associated with traditional CAR T-cell therapies, such as the lengthy ex vivo manufacturing process and the associated risks of lymphodepletion. By employing their proprietary technologies, including VivoVec™ for gene delivery and RACR/CAR™ for in vivo cell programming, Umoja aims to create a scalable and effective treatment option that can generate a robust immune response against cancer cells.

Central to Umoja's strategy is the use of TumorTag™, a small molecule that enhances the targeting of both cancer cells and their supportive stromal cells, thereby improving the efficacy of the immune response. The combination of these technologies allows for a more precise and potent attack on tumors while potentially reducing adverse events associated with treatment. By leveraging these advanced platforms, Umoja Biopharma is committed to pioneering the next generation of immunotherapy, ultimately aiming to provide patients with longer, healthier lives through more effective cancer treatments.

United States

Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Umoja Biopharma

Company Details